Penny stocks with insider buying addresses a key lingering concern among speculators: do the folks that are selling me their business actually believe in their business? I'm telling you, there's nothing worse than putting your money down into an opportunity, only to discover that the very people who are selling you on the idea – indeed, the insiders that know the business the best – are the one...
Immunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset, nuclear receptor related 1 (Nurr1) activator vidofludimus calcium (IMU-838), during the first quarter of 2024. CEO Daniel Vitt highlighted progress in the company's Phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and the twin Phase 3 ENSURE trials in relapsing multiple scle...
– Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – – Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis; Multilayered Intellectual Property Strategy Provides Protection Into 2041 in the United States – – T...
NEW YORK , May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May: May 12-14 and 21-22: Bio€quity Europe 2024. Jessica Breu, Vice President Investor...
– Webcast to be Held at 8:00 am ET on May 8, 2024 – NEW YORK , May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2024, including...
Immunic Inc (NASDAQ:IMUX) has published extended data from its Phase 2 EMPhASIS trial of its lead asset vidofludimus calcium in relapsing-remitting Multiple Sclerosis (RRMS) in the peer-reviewed journal Neurology, Neuroimmunology and Neuroinflammation, an official journal of the American Academy of Neurology. Immunic is developing its small molecule investigational drug vidofludimus calcium as ...
– 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks – – Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis – – Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER...
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.